Table 1.
Characteristics of Tamoxifen Trials Included in Meta-analysis
| Trial | Number of Patients Analyzed | White, % | Postmenopause, % | Age | Dose (mg/day) | Duration of Exposure | Follow-up Interval |
|---|---|---|---|---|---|---|---|
| Risk reduction trials | |||||||
| NSABP P-18 | 13,175 | 96.5 | 60.7 | NR | 20 | 4.0 | 4.0 |
| Royal Mars9 | 2471 | NR | 33.6 | 47 | 20 | 5.8 | 5.8 |
| Italian10,11 | 5408 | NR | NR | 51 | 20 | 5.0 | 6.8 |
| IBIS-I12 | 7139 | NR | 49.1 | 51 | 20 | 5.0 | 4.2 |
| Subtotal | 28,193 | 96.5 | 54.1 | 50.3 | 20 | 4.6 | 4.7 |
| Breast cancer treatment trials | |||||||
| NSABP B1413–15 | 2,885 | 91 | 69.5 | 55.0 | 20 | 5.0 | 8.9 |
| Barner16 | 167 | NR | 79 | 57.5 | 20 | NR | 6.3 |
| Christie17 | 961 | NR | 61.2 | 54.1 | 20 | 10.0 | NR |
| South Swed18,19 | 475 | NR | 100 | NR | 30 | 1.0 | 9.0 |
| DBCG18,20 | 1710 | NR | 100 | NR | 30 | 1.0 | 9.0 |
| Stockholm18,21–23 | 2729 | NR | 100 | NR | 40 | 2.9 | 9.0 |
| ECOG 117824 | 168 | NR | 100 | 70.5 | 20 | 2.0 | 10.0 |
| Alwyn25 | 74 | NR | 100 | 77.5 | 20 | NR | 3.8 |
| Ingle26 | 234 | NR | 100 | 61 | 20 | 1.3 | 5.0 |
| NCCTG27 | 400 | NR | 0 | 43.8 | 20 | 1.3 | 5.3 |
| SWOG28 | 966 | 91 | 100 | 60.5 | 20 | 1.0 | 6.0 |
| Love29 | 140 | NR | 100 | NR | 20 | 5.0 | 5.0 |
| NSABP B2430 | 1798 | 86 | 65 | NR | 20 | 5.0 | 6.2 |
| GROCTA31 | 336 | NR | 53 | NR | 30 | 5.0 | 5.0 |
| Gunderson32 | 350 | NR | NR | NR | 20 | 2.0 | 6.3 |
| Scottish33–36 | 1322 | NR | 82 | 58.9 | 20 | 5.0 | 15 |
| ECOG 617737,38 | 142 | 92 | 100 | 57.5 | 20 | 1.0 | 3.0 |
| ECOG 517737 | 365 | NR | 0 | 57.5 | 20 | 1.0 | 3.6 |
| Cocconi39 | 133 | NR | 100 | 57.5 | 20 | NR | NR |
| Cocconi40 | 49 | NR | 89.7 | 67 | 20 | 0.7 | 6.0 |
| EORTC.E41 | 131 | NR | 100 | NR | 40 | NR | 5.4 |
| EORTC.b45 | 107 | NR | 0 | 43.0 | 40 | 3.0 | 7.3 |
| DBCG 82-B42 | 634 | NR | 0 | NR | 30 | 1 | 10 |
| ATAC43 | 6189 | NR | 100 | 64.2 | 20 | 5 | 2.8 |
| NSABP B-2344 | 1982 | 78 | 45 | NR | 20 | 5 | 5.4 |
| Subtotal | 24,373 | 86.5 | 79.8 | 59.9 | 23.8 | 4.1 | 6.7 |
| Trials unrelated to breast cancer | |||||||
| Rusthoven46 | 195 | NR | NR | 50.6 | 40 | 0.4 | NR |
| Agarwala47 | 56 | NR | 50 | 55 | 20 | NR | NR |
| Cocconi48 | 112 | NR | 72 | 59 | 40 | 0.9 | NR |
| Subtotal | 363 | NR | 69.0 | 53.5 | 37.1 | 0.6 | NR |
| All trials | 52,929 | 91.9 | 66.2 | 54.8 | 21.8 | 4.3 | 5.6 |
NSABP, National Surgical Adjuvant Breast and Bowel Project; IBIS, International Breast Cancer Intervention Study Group; DBCG, Danish Breast Cancer Cooperative Group; ECOG, Eastern Cooperative Oncology Group; NCCTG, North Central Cancer Treatment Group; SWOG, Southwest Oncology Group; GROCTA, Gruppo di Ricerca in Oncologia Clinica e Terapie Associate; EORTC, European Organization for the Research and Treatment of Cancer; ATAC, Arimidex, Tamoxifen Alone or in Combination.